Benjamin George, MD, currently serving as the medical director of oncology at Community Hospital in McCook, Nebraska, and ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective ...

Marija Balic, MD, discusses challenges that remain to the widespread implementation of MRD-guided patient management in TNBC.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the ...

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...

FOLFIRINOX chemotherapy is feasible in selected elderly patients with pancreatic ductal adenocarcinoma, though toxicity ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

The FDA has granted breakthrough therapy designation (BTD) to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...